CBR1 anticorps (AA 201-277)
Aperçu rapide pour CBR1 anticorps (AA 201-277) (ABIN5557348)
Antigène
Voir toutes CBR1 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 201-277
-
Réactivité croisée
- Souris
-
Homologie
- Human,Rat
-
Purification
- Purified by Protein A.
-
Immunogène
- KLH conjugated synthetic peptide derived from human CBR1
-
Isotype
- IgG
-
-
-
-
Indications d'application
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Agent conservateur
- ProClin
-
Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Date de péremption
- 12 months
-
-
- CBR1 (Carbonyl Reductase 1 (CBR1))
-
Autre désignation
- CBR1
-
Sujet
-
Synonyms: Carbonyl reductase [NADPH] 1, CBR1, 15-hydroxyprostaglandin dehydrogenase [NADP(+)], NADPH-dependent carbonyl reductase 1, Prostaglandin 9-ketoreductase, Prostaglandin-E(2) 9-reductase (EC:1.1.1.189), Short chain dehydrogenase/reductase family 21C member 1, CBR, CRN, SDR21C1
Background: NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.
-
ID gène
- 873
-
UniProt
- P16152
Antigène
-